Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Brave New World: Regulatory Flexibility Key To AI Development, Stakeholders Say

Executive Summary

About 130 stakeholders representing a broad spectrum of the health-care industry are asking the US FDA to consider taking a soft touch in any future guidance document addressing artificial intelligence and machine learning devices in order to keep up with developments in the field. Drug lobbyists have also asked the agency to develop guidance that reaches across centers to avoid future conflicts.

You may also be interested in...



GAO/NAS Report On AI In Health Care Critical Of FDA Slowness On SaMD Rulemaking

A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.

HHS Advances AI Priorities In Budget Ask

The US Department of Health and Human Services is asking Congress for $10m in its latest budget request specifically to advance the use of artificial intelligence to regulate FDA products and promote development of AI technology. The ask aligns with President Trump’s vision for government agencies to help make the US a leader in AI and machine learning products.

A Race Against Time? One Man’s Search For Artificial Intelligence Medical Device Standards That Can Keep Up

Pat Baird – Philips Healthcare’s regulatory standards guru – says by the time artificial intelligence/machine learning standards are developed and recognized by regulators, they may already be out-of-date. To speed up the process, he’s taken it upon himself to aggregate the most critical standards to help industry and regulators alike develop guidelines on how such products should be developed and operate.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT125431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel